MTNB — Matinas BioPharma Holdings Share Price
0.000.00%
Last trade - 00:00- $3.10m
- -$4.16m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.41 | ||
| Price to Tang. Book | 0.58 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -246.55% | ||
| Return on Equity | -180.73% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.16 | 0.03 | 3.19 | 1.1 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Directors
- Herbert Conrad NEC (88)
- Jerome Jabbour PRE (46)
- Keith Kucinski CFO (51)
- Hui Liu CTO (53)
- Raphael Mannino CSO (73)
- James Ferguson OTH (67)
- Thomas Hoover OTH (52)
- Theresa Matkovits OTH (53)
- Eric Ende IND (52)
- Natasha Giordano IND (61)
- James Scibetta IND (56)
- Matthew Wikler IND (71)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 21st, 2013
- Public Since
- June 3rd, 2014
- No. of Shareholders
- 97
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 5,086,985
- Address
- Suite 302, 1545 Route 206 South, BEDMINSTER, 07921
- Web
- https://www.matinasbiopharma.com/
- Phone
- +1 9084431860
- Contact
- Jody Cain
- Auditors
- EisnerAmper LLP
Upcoming Events for MTNB
Q2 2025 Matinas BioPharma Holdings Inc Earnings Release
Similar to MTNB
Actinium Pharmaceuticals
NYSE MKT
Aeon Biopharma
NYSE MKT
Armata Pharmaceuticals
NYSE MKT
Azitra
NYSE MKT
Biomx
NYSE MKT
FAQ
What is the Matinas BioPharma Holdings share price?
As of Today at 21:57 UTC, shares in Matinas BioPharma Holdings are trading at $0.61. This share price information is delayed by 15 minutes.
How has the Matinas BioPharma Holdings share price performed this year?
Shares in Matinas BioPharma Holdings last closed at $0.61 and the price had moved by -93.34% over the past 365 days. In terms of relative price strength the Matinas BioPharma Holdings share price has underperformed the S&P500 Index by -94% over the past year.
What are the analyst and broker recommendations for Matinas BioPharma Holdings?
The overall consensus recommendation for Matinas BioPharma Holdings is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Matinas BioPharma Holdings dividend yield?
Matinas BioPharma Holdings does not currently pay a dividend.
Does Matinas BioPharma Holdings pay a dividend?
Matinas BioPharma Holdings does not currently pay a dividend.
When does Matinas BioPharma Holdings next pay dividends?
Matinas BioPharma Holdings does not currently pay a dividend.
How do I buy Matinas BioPharma Holdings shares?
To buy shares in Matinas BioPharma Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Matinas BioPharma Holdings?
As of the previous close price of $0.61, shares in Matinas BioPharma Holdings had a market capitalisation of $3.10m.
Where are Matinas BioPharma Holdings shares listed?
Here are the trading details for Matinas BioPharma Holdings:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: MTNB
What kind of share is Matinas BioPharma Holdings?
Based on an overall assessment of its quality, value and momentum Matinas BioPharma Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Matinas BioPharma Holdings share price forecast for 2025?
The analyst consensus target price for shares in Matinas BioPharma Holdings is $30.00. That is 4818.03% above the last closing price of $0.61.
Analysts covering Matinas BioPharma Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$1.50 for the next financial year.
Find out moreWhat is the trend in the Matinas BioPharma Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Matinas BioPharma Holdings. Over the past six months, its share price has outperformed the S&P500 Index by +5.31%.
As of the last closing price of $0.61, shares in Matinas BioPharma Holdings were trading -73.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Matinas BioPharma Holdings PE Ratio?
The Matinas BioPharma Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.61.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Matinas BioPharma Holdings?
Matinas BioPharma Holdings' management team is headed by:
- Herbert Conrad - NEC
- Jerome Jabbour - PRE
- Keith Kucinski - CFO
- Hui Liu - CTO
- Raphael Mannino - CSO
- James Ferguson - OTH
- Thomas Hoover - OTH
- Theresa Matkovits - OTH
- Eric Ende - IND
- Natasha Giordano - IND
- James Scibetta - IND
- Matthew Wikler - IND